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IMPORTANCE To date, the clinical features of the various subtypes of conjunctival lymphoma
(CL) have not been previously evaluated in a large cohort.
OBJECTIVE To characterize subtype-specific clinical features of CL and their effect on patient
outcome.
DESIGN, SETTING, AND PARTICIPANTS A retrospectivemulticenter studywas performed.
Patient data were collected from January 1, 1980, through December 31, 2010. The dates of
the analysis were May 15, 2015, to August 20, 2015. Themedian follow-up period was 43
months. Seven eye cancer centers were involved in the study. In total, 268 patients with CL
were identified, 5 of whomwere excluded because of missing clinical data.
MAIN OUTCOMES ANDMEASURES Overall survival, disease-specific survival, and
progression-free survival were the primary end points.
RESULTS Two hundred sixty-three patients with CL were included in the study. Their mean
age was 61.3 years, and 55.1% (145 of 263) were female. All lymphomas were of B-cell type.
Themost frequent subtype was extranodal marginal zone lymphoma (EMZL) (68.4% [180 of
263]), followed by follicular lymphoma (FL) (16.3% [43 of 263]), mantle cell lymphoma (MCL)
(6.8% [18 of 263]), and diffuse large B-cell lymphoma (DLBCL) (4.6% [12 of 263).
Conjunctival lymphoma commonly manifested in elderly individuals (age range, 60-70 years
old), with EMZL having a female predilection (57.8% [104 of 180]) andMCL having amarked
male predominance (77.8% [14 of 18]). Unlike EMZL and FL, DLBCL andMCLwere frequently
secondary diseases (41.7% [5 of 12] and 88.9% [16 of 18], respectively), with MCL showing a
frequent occurrence of stage IVE lymphoma (61.1% [11 of 18]) and bilateral manifestation
(77.8% [14 of 18]). Localized disease (stage IE or IIE) was commonly treated with external
beam radiation therapy (EBRT) with or without chemotherapy, while widespread lymphoma
(stage IIIE or IVE) andMCL of any stage weremanaged with chemotherapy with or without
EBRT. Diffuse large B-cell lymphoma andMCL had a poor prognosis, with 5-year
disease-specific survival of 55.0% and 9.0%, respectively, in contrast to EMZL (97.0%) and
FL (82.0%). Further survival predictors included age (EMZL), sex (FL), and Ann Arbor staging
classification (EMZL and FL). The American Joint Committee on Cancer TNM staging showed
limited prognostic usefulness, only being able to predict survival for patients with DLBCL.
CONCLUSIONS AND RELEVANCE Conjunctival lymphoma consists of mainly 4 subtypes of
B-cell non-Hodgkin lymphoma: EMZL, FL, MCL, and DLBCL. Mantle cell lymphoma is
characterized by a particularly high frequency of secondary disease of stage IVE and bilateral
manifestation. The histological subtype is themain outcome predictor, with MCL and DLBCL
having amarkedly poorer prognosis than EMZL and FL.
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L ymphomas are neoplasms derived from clonal prolif-erations of lymphocytes and comprise a diverse groupof diseaseswithmore than40different subtypes.1 Both
nodal and extranodal forms can occur. Ocular adnexal lym-
phomas (OALs)constitute2%ofall extranodal lymphomas,and
25% to 30% of all OALs are located in the conjunctiva.2,3
Conjunctival lymphoma(CL) consistsofmainly4subtypes
ofB-cellnon-Hodgkin lymphoma(B-NHL).The2 low-gradema-
lignant neoplasias are extranodal marginal zone lymphoma
(EMZL) and follicular lymphoma (FL), while the 2 high-grade
B-NHLsarediffuse largeB-cell lymphoma (DLBCL) andmantle
cell lymphoma (MCL). Extranodal marginal zone lymphoma
constitutesmore than one-half of the conjunctival B-NHLs.3,4
Conjunctival lymphomaoccursmost frequently inmiddle-
aged andelderly individuals as a painless patch that is salmon
pink.4-6 Generally, it is described as an indolent disease with
a favorable survival.4,6However,previous studies6,7 ofCLhave
been based on cohorts of patients with different lymphoma
subtypes.Becauseof thegreatdiversity inclinicalbehaviorand
prognosis of different lymphoma subtypes, analyses focus-
ingoneach subtype areneeded. Therefore, the aimof thepre-
sent study was to evaluate subtype-specific clinical features
of CL and their effect on survival in a large cohort of patients
from 7 eye cancer centers.
Methods
Study Design
Eligible patients with a diagnosis of CL were identified from
the databases of 7 eye cancer centers. The cases were col-
lected from January 1, 1980, throughDecember 31, 2010. The
dates of the analysis were May 15, 2015, to August 20, 2015.
For histopathological examination, the specimens were
stainedwith hematoxylin-eosin and analyzed immunohisto-
chemicallyusingapanelof antibodies.Currentguidelines1 rec-
ommend the following panel of antibodies for small cell lym-
phomas:CD3,CD5,CD10,CD20,CD23,CD79α,cyclinD-1,Bcl-2,
Bcl-6, multiple myeloma oncogene 1 (MUM-1), methylation-
inhibited binding protein 1 (MIB-1), and κ and λ light-chains.
Guidelines recommend the following panel of antibodies for
large cell lymphomas: CD3, CD5, CD10, CD20, CD30, CD79α,
Bcl-2, Bcl-6, MUM-1, and MIB-2. Because the data collection
spans over 30years andencompasses 7 international eye can-
cer centers, not all the sampleswere analyzed in this uniform
manner.However, the cancer centershave reviewed the speci-
mens based on the current guidelines and reclassified them
according to World Health Organization Classification of
Tumours of Haematopoietic and Lymphoid Tissues.1
The study followed the tenets of the Declaration of
Helsinki and the Health Insurance Portability and Account-
ability Act of 1996 in the United States. Institutional review
board and health information privacy agency approvals were
obtained from the Danish Data Protection Agency.
Clinical Data
Clinical datawere recorded.Thesevariables includedage, sex,
symptoms and clinical findings, laterality, systemic involve-
ment according to theAnnArbor staging classification,8 treat-
ment modalities and response to therapy, survival duration,
and cause of death.
Systemic involvement and laterality were determined
using clinical information and diagnostic tools available at
the time of diagnosis. Currently, a complete diagnostic pro-
cedure includes full-body positron emission tomography–
computed tomography, computed tomography or magnetic
resonance imaging of the conjunctiva, and a bone marrow
biopsy.
PrimaryCLwasdefinedasabiopsy-verified lymphomalim-
ited to theocular adnexal region (OAR) (stage IE)withorwith-
out involvement of unilateral preauricular or submandibular
lymph nodes or adjacent structures (stage IIE) and no history
of lymphoma disease. Therefore, secondary lymphoma in-
cluded systemic lymphoma with a secondary manifestation
in the OAR and ocular adnexal relapse of systemic lym-
phoma. The extent of ocular adnexal involvement of primary
lymphomas was also evaluated according to the seventh edi-
tion of the American Joint Committee on Cancer (AJCC) TNM
staging system for OAL.9
Statistical Analysis
Overall survival (OS), disease-specific survival (DSS), andpro-
gression-free survival (PFS)were considered the primary end
points. Overall survival was defined as the date of diagnosis
to the date of death fromany cause or the date of last contact,
the latterbeingacensoredevent.Disease-specific survivalwas
defined as thedate of diagnosis to thedate of death from lym-
phoma or to the date of last contact, the latter being a cen-
soredevent. Progression-free survivalwas calculated fromthe
date of diagnosis to either the date of first relapse or progres-
sion after initial treatment to thedate of death fromany cause
or to the date of last contact, with the last 2 being censored
events. Life tables and Kaplan-Meier plots were generated to
visualize survival outcomes, and different risk groups were
comparedusing the log-rank test. Individual risk factorswere
compared using the χ2 test. Statistical calculations were per-
formed using a software program (IBMSPSS Package, version
22; IBM Corporation).
Key Points
Question:What are the subtype-specific clinical features
of conjunctival lymphoma and their effect on patient outcome?
Findings: Conjunctival mantle cell lymphoma and diffuse large
B-cell lymphoma are frequently secondary diseases, with mantle
cell lymphoma having a high occurrence of stage IVE lymphoma
and bilateral manifestation. These lesions have amarkedly poorer
prognosis (5-year disease-specific survival, 55.0% for diffuse large
B-cell lymphoma and 9.0% for mantle cell lymphoma) than their
low-grade counterparts extranodal marginal zone lymphoma and
follicular lymphoma (5-year disease-specific survival, 97.0% and
82.0%, respectively).
Meaning: These data suggest that the histological subtype is a
major outcome predictor for patients with conjunctival lymphoma.
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Results
In total, 268 patients with CL were identified from the data-
bases of the following7 eye cancer centers: Copenhagen,Den-
mark (n = 84); Liverpool, England (n = 70); Hyderabad, India
(n = 34);NewYork,NewYork (n = 31);Houston,Texas (n = 31);
Atlanta, Georgia (n = 10); and Melbourne, Australia (n = 8)
(Table 1). Five patients from Copenhagen were excluded be-
causeofmissingdata, leaving263patients for analysis.All CLs
were of B-NHL type. Seven subtypes of B-NHL were identi-
fied:EMZL (n = 180), FL (n = 43),MCL (n = 18),DLBCL (n = 12),
plasmacytoma (PL) (n = 5), lymphoplasmacytic lymphoma
(LPL) (n = 4), and Burkitt lymphoma (n = 1). The median
follow-up period was 43 months.
Extranodal Marginal Zone Lymphoma
Clinical Features
In total, 180 cases (68.4%) of EMZLwere identified. One hun-
dred four patients (57.8%)were female (Table 2). Themedian
agewas60years (age range,8-92years).Mostpatientshadpri-
mary disease (158 of 180 [87.8%]) with a unilateral manifes-
tation (147 of 180 [81.7%]). Tumor or swelling (90.3% [112 of
124]) was the most common symptom, and the most com-
monclinical signwasa tumormass (90.3%[112of 124]) (eTable
in the Supplement) (Figure 1). The median symptom dura-
tionwas6months (range,0.5-48months).Most patientswere
initially seenwith stage IE lymphoma (156 of 174 [89.7%]) ac-
cording to the Ann Arbor staging classification (Table 2). The
AJCC TNM staging was performed on the 159 patients with
primary EMZL, 123 (77.4%) of whom had stage T1 disease.
Treatment
Patients with localized disease (stage IE or IIE) were mainly
treated with EBRT with or without chemotherapy (90 of 109
[82.6%]), while patients with widespread disease (stage IIIE
or IVE)were commonlymanagedwith chemotherapywith or
withoutEBRT(6of9 [66.7%]) (Table3). ThemedianEBRTdose
was20Gy (range, 15-45Gy) (toconvert to rad,multiplyby100).
The applied chemotherapy types included cyclophospha-
mide, vincristine, andprednisone (CVP), aswell as cyclophos-
phamide, hydroxydaunorubicin, vincristine, and prednisone
Table 1. Eye Cancer Center Distribution of Patients by Subtype of Conjunctival Lymphoma
Subtype
Eye Cancer Center
CPH
(n = 79)
LIV
(n = 70)
HYD
(n = 34)
NY
(n = 31)
HOU
(n = 31)
ATL
(n = 10)
MEL
(n = 8)
EMZL
No. of patients 53 39 26 24 24 9 5
Median age, y 67 65 48 60 48 53 52
Male to female ratio 2:3 1:3 3:1 3:5 3:5 4:5 1:4
FL
No. of patients 9 14 7 6 4 1 2
Median age, y 69 70 64 71 56 62 61
Male to female ratio 1:2 1:4 6:1 1:1 1:1 1:0 2:0
DLBCL
No. of patients 4 5 1 0 2 0 0
Median age, y 74 75 82 NA 48 NA NA
Male to female ratio 1:3 3:2 1:1 NA 1:1 NA NA
MCL
No. of patients 12 4 0 1 1 0 0
Median age, y 70 70 NA 73 34 NA NA
Male to female ratio 3:1 4:0 NA 0:1 1:0 NA NA
PL
No. of patients 0 5 0 0 0 0 0
Median age, y NA 62 NA NA NA NA NA
Male to female ratio NA 1:4 NA NA NA NA NA
LPL
No. of patients 1 3 0 0 0 0 0
Median age, y 79 69 NA NA NA NA NA
Male to female ratio 0:1 0:3 NA NA NA NA NA
BL
No. of patients 0 0 0 0 0 0 1
Median age, y NA NA NA NA NA NA 15
Male to female ratio NA NA NA NA NA NA 1:0
Abbreviations: ATL, Atlanta, Georgia; BL, Burkitt lymphoma; CPH, Copenhagen,
Denmark; DLBCL, diffuse large B-cell lymphoma; EMZL, extranodal marginal
zone lymphoma; FL, follicular lymphoma; HOU, Houston, Texas;
HYD, Hyderabad, India; LIV, Liverpool, England; LPL, lymphoplasmacytic
lymphoma; MCL, mantle cell lymphoma; MEL, Melbourne, Australia; NA, not
applicable; NY, New York, New York; PL, plasmacytoma.
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(CHOP) in combination with rituximab (R-CHOP), alkylating
agents, and unspecified chemotherapy.
Treatment Outcome and Survival
Disease recurrence was observed in 37.9% (64 of 169) of
patients with conjunctival EMZL (Table 2). The time to
recurrence was accessible in 33 of these patients, with a
median of 24 months (range, 3-192 months). Survival data
were available for all 180 patients with EMZL. The median
PFS was 11.3 years. The OS rates at 5, 10, and 20 years were
83.0%, 65.0%, and 43.0%, respectively (median, 16.3 years;
95% CI, 11.9-20.7 years), whereas the 5-year, 10-year, and
20-year DSS rates were 97.0%, 93.0%, and 89.0%, respec-
tively (Figure 2A). Analysis of low-grade CLs, including
EMZL, showed that an Ann Arbor stage higher than IE was
associated with decreased DSS (P = .03) (Figure 2B). Fur-
thermore, patients older than 60 years with EMZL had
poorer DSS (20-year DSS, 83.0%) than younger patients
(20-year DSS, 100.0%) (P = .01).
Follicular Lymphoma
Clinical Features
Forty-three cases (16.3%) of FL were identified from the
database. Twenty-three patients (53.5%) were female
(Table 2). The median age was 67 years (age range, 33-89
years). Most patients had primary CL (27 of 43 [62.8%]) with
unilateral manifestation (29 of 43 [67.4%]). Tumor or swell-
ing (21 of 25 [84.0%]) was the most common symptom, and
the most common clinical sign was a tumor mass (22 of 26
[84.6%]). The median symptom duration was 6 months
(range, 2-48 months) (eTable in the Supplement). Most
patients were initially seen with stage IE lymphoma (28 of
43 [65.1%]) according to the Ann Arbor staging classification
(Table 2). The AJCC TNM staging was performed on the 28
Table 2. Clinical and Staging Characteristics of Patients by Subtype of Conjunctival Lymphomaa
Characteristic
No. (%) of Patients
EMZL
(n = 180)
FL
(n = 43)
DLBCL
(n = 12)
MCL
(n = 18)
PL
(n = 5)
LPL
(n = 4)
BL
(n = 1)
Sex
Male 76 (42.2) 20 (46.5) 6 (50.0) 14 (77.8) 1 0 1
Female 104 (57.8) 23 (53.5) 6 (50.0) 4 (22.2) 4 4 0
Age at presentation, y
≤60 92 (51.1) 16 (37.2) 2 (16.7) 1 (5.6) 1 1 1
>60 88 (48.9) 27 (62.8) 10 (83.3) 17 (94.4) 4 3 0
Primary disease 158 (87.8) 27 (62.8) 7 (58.3) 2 (11.1) 5 2 1
Disseminated disease 13 (7.2) 10 (23.3) 3 (25.0) 12 (66.7) 0 1 0
Relapsed 9 (5.0) 6 (14.0) 2 (16.7) 4 (22.2) 0 0 0
Laterality
Unilateral 147 (81.7) 29 (67.4) 10 (83.3) 4 (22.2) 4 3 1
Bilateral 33 (18.3) 14 (32.6) 2 (16.7) 14 (77.8) 1 0 0
Ann Arbor stage
IE 156/174 (89.7) 28 (65.1) 7 (58.3) 2 (11.1) 4 1 1
IIE 6/174 (3.4) 5 (11.6) 1 (8.3) 1 (5.6) 1 1 0
IIIE 1/174 (0.6) 4 (9.3) 3 (25.0) 4 (22.2) 0 0 0
IVE 11/174 (6.3) 6 (14.0) 1 (8.3) 11 (61.1) 0 1 0
AJCC TNM stage
T1 123/159 (77.4) 19/28 (67.9) 3/6 (50.0) 1/3 (33.3) 4 2 1
T2 35/159 (22.0) 5/28 (17.9) 3/6 (50.0) 2/3 (66.7) 0 0 0
T3 1/159 (0.6) 4/28 (14.3) 0 0 0 0 0
T4 0 0 0 0 1 0 0
Recurrence
Yes 64/169 (37.9) 18/42 (42.9) 8 (66.7) 13/16 (81.3) 5 3 0
No 105/169 (62.1) 24/42 (57.1) 4 (33.3) 3/16 (18.8) 0 1 0
Site of recurrence
OAR 31/50 (62.0) 6/18 (33.3) 0 1/12 (8.3) 0 0 0
OAR plus nodal and/or extranodal 5/50 (10.0) 4/18 (22.2) 3/7 (42.9) 7/12 (58.3) 5 0 0
Nodal and/or extranodal 14/50 (28.0) 8/18 (44.4) 4/7 (57.1) 4/12 (33.3) 0 3 0
Disease status at last follow-up
Complete remission 110 (61.1) 23 (53.5) 2 (16.7) 4 (22.2) 0 0 1
Alive with disease 28 (15.6) 10 (23.3) 1 (8.3) 2 (11.1) 1 1 0
Dead from lymphoma 7 (3.9) 8 (18.6) 6 (50.0) 11 (61.1) 3 2 0
Dead from other causes than lymphoma 35 (19.4) 2 (4.7) 3 (25.0) 1 (5.6) 1 0 0
Abbreviations: AJCC, American Joint Committee on Cancer; BL, Burkitt
lymphoma; DLBCL, diffuse large B-cell lymphoma; EMZL, extranodal marginal
zone lymphoma; FL, follicular lymphoma; LPL, lymphoplasmacytic lymphoma;
MCL, mantle cell lymphoma; OAR, ocular adnexal region; PL, plasmacytoma.
a Data are not specified for all patients.
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patients with conjunctival FL, 19 (67.9%) of whom were
seen with stage T1 disease.
Treatment
Patients with localized disease were mainly treated with
EBRT with or without chemotherapy (22 of 24 [91.7%]),
while patients with widespread disease were commonly
managed with chemotherapy with or without EBRT (8 of 10
[80.0%]) (Table 3). The median EBRT dose was 20 Gy
(range, 20-45 Gy). The applied chemotherapy types
included CHOP, R-CHOP, alkylating agents, antimetabolites,
and unspecified chemotherapy.
Treatment Outcome and Survival
Disease recurrence was observed in 42.9% (18 of 42) of
patients with conjunctival FL (Table 2). The time to recur-
rence was accessible in 6 of these patients, with a median of
28 months (range, 13-161 months). Survival data were avail-
able for all 43 patients with FL. The median PFS was 6.7
years. The OS rates at 5 and 10 years were 75.0% and 59.0%,
respectively, whereas the 5-year and 10-year DSS rates were
82.0% and 65.0%, respectively (Figure 2A). Analysis of low-
grade CLs, including FL, showed that an Ann Arbor stage
higher than IE was associated with decreased DSS (P = .03)
(Figure 2B). Furthermore, female patients with FL had
Figure 1. Clinical and Histological Findings of EMZL
Clinical presentation of conjunctival EMZLA
Tumor cells reacting with CD79αE
Computed tomography showing the tumor mass
(arrowhead)
B
Bcl-2 positivity in the tumor cells of conjunctival EMZLF
Diffuse pattern of small centrocyte-like cells
in EMZL (C and D)
C Hematoxylin-eosin staining (C and D)D
50 µm 50 µm
50 µm 50 µm
EMZL indicates extranodal marginal
zone lymphoma.
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poorer DSS (10-year DSS, 43.0%) than male patients (10-year
DSS, 100.0%) (P = .008).
Diffuse Large B-Cell Lymphoma
Clinical Features
Twelve cases of DLBCL (4.6%) were identified from the data-
base. Sixpatients (50.0%)weremale (Table2). Themedianage
was74years (agerange,30-89years).Almosthalfofall thecases
weresecondary lymphomas(5of12[41.7%]).Mostpatientswere
initially seen with unilateral disease (10 of 12 [83.3%]). Tumor
or swelling (3of 7 [42.9%]) and irritationorpain (3of 7 [42.9%])
were the most common symptoms, while the most common
clinical sign was a tumor mass (5 of 7 [71.4%]) (eTable in the
Supplement). The median symptom duration was 5 months
(range,0.5-48months). Justoverhalf of thepatientswere seen
with stage IE lymphoma (7 of 12 [58.3%]) according to the Ann
Arborstagingclassification(Table2).TheAJCCTNMstagingwas
performed on 6 patients with primary DLBCL, 3 of whom had
stage T1 disease and 3 of whomhad stage T2 disease.
Treatment
Patients with localized disease were mainly treated with
EBRT with or without chemotherapy (6 of 8 [75.0%]), while
patients with widespread lymphoma were managed with
chemotherapy with or without EBRT (4 of 4) (Table 3).
Information on EBRT doses was available in 3 patients, and
the median dose was 30 Gy (range, 26-40 Gy). The applied
chemotherapy types included R-CHOP and unspecified
chemotherapy.
Treatment Outcome and Survival
Disease recurrence was observed in 66.7% (8 of 12) of pa-
tients with conjunctival DLBCL (Table 2). The time to recur-
rence was accessible in 4 of these patients, with a median of
10months (range, 2-23months). Survival datawere available
for all 12 patientswith DLBCL. Themedian PFSwas 3.5 years.
The 5-year and 10-year OS was 44.0% and 16.0%, respec-
tively (median, 4.7 years; 95% CI, 0.1-7.9 years), whereas the
5-yearand10-yearDSSwas55.0%and39.0%, respectively (me-
dian, 5.8 years; 95% CI, 0.1-10.1 years) (Figure 2A). Advanced
AJCCTNMstage (T2 vs T1)was associatedwith a poor DSS for
patients with conjunctival DLBCL (P = .03).
Mantle Cell Lymphoma
Clinical Features
Eighteen cases of MCL (6.8%) were identified from the data-
base. Fourteen patients (77.8%) were male (Table 2). The
median age was 72 years (age range, 34-90 years). Most
patients had secondary disease (16 of 18 [88.9%]) with a
bilateral manifestation (14 of 18 [77.8%]). Tumor or swelling
(10 of 14 [71.4%]) was the most common symptom, and the
most common clinical signs were a tumor mass and chemo-
sis (6 of 14 [42.9%], respectively) (eTable in the Supple-
ment). The median symptom duration was 4 months (range,
1-24 months). Most patients were initially seen with stage
IVE MCL (11 of 18 [61.1%]) according to the Ann Arbor stag-
ing classification (Table 2). The AJCC TNM staging was per-
formed on the 2 cases of primary conjunctival MCL, both of
which were T2 disease.
Table 3. Management of Patients by Subtype of Conjunctival Lymphoma
Stage
No. (%) of Patientsa
EBRT EBRT Plus CTX CTX
CTX Plus
Rituximab
EBRT and CTX
Plus Rituximab Rituximab Surgery
EMZL
IE or IIE 75 (68.8) 15 (13.8) 7 (6.4) 1 (9.2) 0 9 (8.3) 2 (1.8)
IIIE or IVE 2 (22.2) 1 (11.1) 4 (44.4) 1 (11.1) 0 1 (11.1) 0
FL
IE or IIE 14 (58.3) 8 (33.3) 2 (8.3) 0 0 0 0
IIIE or IVE 1 (10.0) 3 (30.0) 3 (30.0) 2 (20.0) 0 1 (10.0) 0
DLBCL
IE or IIE 5 (62.5) 1 (12.5) 0 2 (25.0) 0 0 0
IIIE or IVE 0 3 (75.0) 0 1 (25.0) 0 0 0
MCL
IE or IIE 0 0 1 0 1 0 0
IIIE or IVE 2 (14.3) 5 (35.7) 2 (14.3) 5 (35.7) 0 0 0
PLb
IE or IIE 4 1 0 0 0 0 0
LPLc
IE or IIE 2 0 0 0 0 0 0
BLd
IE or IIE 0 0 1 0 0 0 0
Abbreviations: BL, Burkitt lymphoma; CTX, chemotherapy; DLBCL, diffuse large
B-cell lymphoma; EBRT, external beam radiation therapy; EMZL, extranodal
marginal zone lymphoma; FL, follicular lymphoma; LPL, lymphoplasmacytic
lymphoma; MCL, mantle cell lymphoma; PL, plasmacytoma.
a Data are not specified for all patients. All percentages are row percentages.
bAll conjunctival PLs were stage IE or IIE disease.
c No treatment data were available for LPL higher than stage IIE.
d The case of conjunctival BL was stage IE disease.
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Treatment
Patients with conjunctival MCL mainly received chemo-
therapy with or without EBRT treatment for both localized
(2 of 2) andwidespreaddisease (12 of 14 [85.7%]) (Table 3). In-
formation onEBRTdosewas available in one patient,who re-
ceived30Gy.Theappliedchemotherapy types includedCHOP,
R-CHOP, and alkylating agents, as well as hyperfractionated
cyclophosphamide, vincristine, doxorubicin, and dexameth-
asone (hyper-CVAD) and unspecified chemotherapy.
Treatment Outcome and Survival
Disease recurrence was observed in 81.3% (13 of 16) of pa-
tients with conjunctival MCL (Table 2). The time to recur-
rence was accessible in 7 of these patients, with a median of
24 months (range, 4-49 months). Survival data were avail-
able forall 18patientswithMCL.ThemedianPFSwas2.7years.
Overall survival andDSSat 5years and 10yearswere9.0%and
0.0%, respectively (median, 3.9 years; 95% CI, 2.9-4.8 years)
(Figure 2A). Survival outcomes did not appear to be different
in patients who received rituximab-containing chemo-
therapy compared with other treatment regimens (P = .50).
Plasmacytoma
Five cases of PL were identified from the database. The diag-
nosis of PLwasmade in associationwith the clinical informa-
tion presented at a multidisciplinary tumor board. Four pa-
Figure 2. Disease-Specific Survival Among PatientsWith Conjunctival Lymphoma
Disease-specific survival by subtype of conjunctival lymphomaA Disease-specific survival by Ann Arbor classification stageB
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A, Disease-specific survival is associated with the subtype of conjunctival
lymphoma. EMZL has themost favorable disease-specific survival, while MCL
has the poorest disease-specific survival (P = <.001). B, Stage >IE is associated
with lower disease-specific survival than stage IE for low-grade conjunctival
lymphomas (P = .03). BL indicates Burkitt lymphoma; DLBCL, diffuse large
B-cell lymphoma; EMZL, extranodal marginal zone lymphoma; FL, follicular
lymphoma; LPL, lymphoplasmacytic lymphoma; MCL, mantle cell lymphoma;
and PL, plasmacytoma.
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tientswere female, andthemedianagewas62years (age range,
16-64 years) (Table 2). Unilateral lesionswere seen in 4 cases.
All 5 PLswereprimarydisease, 4 stage IE lymphomas andone
stage IIE lymphoma. These conjunctival lesions were man-
aged with EBRT with or without chemotherapy (Table 3). All
5 patients had recurrence of disease. Survival datawere avail-
able for all 5 PL cases. Overall survival andDSS at 5 yearswere
80.0%(4of5) (median,8.5years; 95%CI, 5.5-11.9years),while
OS at 10 years was 0% (0 of 5) (Figure 2A).
Lymphoplasmacytic Lymphoma
Four cases of LPL were identified from the database. The di-
agnosis of LPL was made in association with the clinical in-
formation presented at a multidisciplinary tumor board (eg,
raised serum IgM levels and increased serum viscosity val-
ues). All 4 patients with LPL in the study were female, with a
median age of 74 years (age range, 26-83 years) (Table 2). Uni-
lateral disease (3 of 3) and primary presentation (2 of 3) were
common among patients with LPL. These conjunctival le-
sions were all managed with EBRT (Table 3). All patients had
recurrence of disease. Survival data were available for 3 pa-
tientswithLPL.Overall survival andDSSat5yearsand10years
were 100% (3 of 3) and 0% (0 of 3), respectively (median, 9.4
years; 95% CI, 1.1-17.7 years) (Figure 2A).
Burkitt Lymphoma
One patient with Burkitt lymphoma was identified from the
database. He was 15-year-old boy who had primary CL (stage
IE) with unilateral manifestation. The patient received
2 cycles of CHOP, with a cumulative dose of doxorubicin at
120 mg/m2. The patient was in complete remission at 25
months after the diagnosis.
Discussion
Among 263patients, CLwas found to consist ofmainly 4 sub-
types of B-NHL: EMZL (68.4% [n = 180]), FL (16.3% [n = 43]),
MCL (6.8%[n = 18]), andDLBCL (4.6%[n = 12]). Thehistologi-
cal subtype was the main outcome predictor, with MCL and
DLBCL (5-year DSS, 9.0% and 55.0%, respectively) having a
markedly poorer prognosis than EMZL and FL (5-year DSS,
97.0% and 82.0%, respectively). This result is in accord with
our group’s andothers’ previous findings.4,10,11 Ageolder than
60years (forEMZL), femalesex (forFL),AnnArborstagehigher
than IE (for EMZL andFL), and T category exceeding T1 of the
AJCCTNMstagingclassification (forDLBCL)were likewisepre-
dictive of poor outcome.
The retrospective design of this multicenter study poses
some inherent limitations. The datawere pooled across 7 eye
cancer centers over a 30-year period, entailing incomplete
medical records and varying diagnostic methods. Further-
more, themedian follow-upwas43months,which—given the
indolent nature of many of the lesions—may not have been
enough time to detect the outcome variables. On the other
hand, multicenter studies like this one provide valuable in-
formation on rare lesions and should be encouraged to obtain
a reasonable number of patients.
The predominance of EMZL, observed in the conjunc-
tiva, is found atmany othermucosa-associated lymphoid tis-
sue (MALT) sites, such as the stomach and the lungs,12,13 with
the exception of Waldeyer ring (nasopharynx and orophar-
ynx) and Peyer patches (ileum), which are seldom sites for
EMZL todevelop,despite theabundanceofMALT.14-16The fre-
quencyofDLBCL ismarkedly low in theconjunctiva (5%)com-
paredwith the remainingOAR(13%)3andcomparedwithmany
MALT sites, particularly Waldeyer ring, where DLBCL is the
dominant subtype.12,14,15,17,18 The low frequency of DLBCL in
the conjunctiva is corroborated by the results of other
studies.3,4,11
Extranodal marginal zone lymphoma was found to be
more common in New York and Hyderabad than in
Liverpool (P = .04), which may be due to an underlying
selection bias because the aggressive subtypes were prob-
ably primarily managed in the largest eye cancer centers.
Furthermore, EMZL and FL in Hyderabad, unlike at other
participating centers, had a marked male predominance.
This finding may be related to differing demographic pat-
terns among geographical regions but is consistent with
observations of our group’s multicenter study19 of ocular
adnexal FL.
Current lymphoma treatment guidelines recommend
R-CHOP or R-CHOP–like chemotherapy for management of
MCLandDLBCL, aswell as high-stageEMZLandFLwithhigh
tumor burden.20-23 This type of therapywas only applied in 6
MCLs, 3 DLBCLs, 2 FLs, and 2 EMZLs in the present study,
whichmay be owing to the fact that the study spanned over a
30-year period and rituximab has only been available since
1997. This rationalemaypartially explain the fact that theout-
comeof conjunctivalDLBCLandMCL in thepresent studywas
poorer compared with survival rates of these lymphomas in
general.24-27
The AJCC TNM staging classification allowed a precise
characterization of the extent of local disease for CLs, which
in turn provided a larger staging distribution.28 The predic-
tive ability of the T category for patients with DLBCL is con-
sistentwith the resultsofourgroup’smulticenter studyofocu-
lar adnexalDLBCL.29However,becausenoassociations todate
have been detected between the T category and patient out-
come for the remaining subtypes, the AJCC TNMstagingmay
be of limited prognostic usefulness for CLs.
Conclusions
The results of this study in 263 patients confirm that CL
consists of mainly 4 subtypes of B-NHL: EMZL (68.4%
[n = 180]), FL (16.3% [n = 43]), MCL (6.8% [n = 18]), and
DLBCL (4.6% [n = 12]). The histological subtype was identi-
fied as the major outcome predictor, with MCL and DLBCL
having a markedly poorer prognosis than EMZL and FL. The
study was limited by its retrospective nature and loss to
follow-up owing to the indolent nature of some of the CLs.
However, multicenter studies like this one should be
encouraged for future trials to include a reasonable number
of patients.
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